Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2015 10:24 ET | Source: Immunomedics, Inc.

Immunomedics Reports Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal Cancer

CHICAGO, June 2, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced an interim analysis of a mid-stage clinical study showed that its first-in-class antibody-drug conjugate...
June 02, 2015 10:12 ET | Source: Immunomedics, Inc.

Immunomedics Announces Durable Responses in Metastatic Lung Cancer Patients Treated With Sacituzumab Govitecan

CHICAGO, June 2, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), demonstrated...
June 01, 2015 09:00 ET | Source: Immunomedics, Inc.

Immunomedics Reports Promising Results With Sacituzumab Govitecan in Patients With Metastatic Gastrointestinal Cancers

CHICAGO, June 1, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that a majority of patients with heavily-pretreated, metastatic gastrointestinal cancers responded to...
June 01, 2015 07:00 ET | Source: Immunomedics, Inc.

Immunomedics Reports Complete Responses in Patients With Metastatic Triple-Negative Breast Cancer After Sacituzumab Govitecan Treatment

CHICAGO, June 1, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that among 49 patients with metastatic triple-negative breast cancer (TNBC) evaluated for response to...
May 26, 2015 08:30 ET | Source: Immunomedics, Inc.

Immunomedics to Present at Jefferies 2015 Global Healthcare Conference

MORRIS PLAINS, N.J., May 26, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company will present at Jefferies 2015 Global Healthcare Conference at 11:00 a.m....
May 15, 2015 12:30 ET | Source: Immunomedics, Inc.

Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan for Non-Small Cell Lung Cancer Therapy

MORRIS PLAINS, N.J., May 15, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) designating as a...
May 14, 2015 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Announces Five Presentations at 2015 ASCO Focusing on Antibody-Drug Conjugate Programs

MORRIS PLAINS, N.J., May 14, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that two of its five abstracts submitted to the 2015 Annual Meeting of the American Society of...
May 12, 2015 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Extends U.S. Patent Protection for Sacituzumab Govitecan to 2033

MORRIS PLAINS, N.J., May 12, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced the issuance of U.S. Patent No. 9,028,833 for a new patent family "Dosages of immunoconjugates...
May 06, 2015 16:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Third Quarter Fiscal 2015 Results and Clinical Program Developments

MORRIS PLAINS, N.J., May 6, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported financial results for the third quarter ended March 31, 2015. The Company also highlighted recent...
April 30, 2015 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2015 Financial Results

MORRIS PLAINS, N.J., April 30, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Thursday, May 7, 2015 at 10:00...